Key facts
- Dose’s last known valuation is $347.0M (May 2025).
- It has raised $62.1M; the latest was Later Stage VC ($47.0M) in May 2025.
- Notable investors include Unilever Ventures, Melitas Ventures, Vanterra Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Dose
- ·The full record, as it builds
Funding rounds
No funding rounds for Dose are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dose
Producer of organic wellness drinks and shots intended to offer functional support for a healthier body every day. The company's products include turmeric, aloe vera, elderberry, and milk thistle, which benefit the liver, skin, immune system, and muscles, providing customers with shots that contain potent ingredients that help them to keep their bodies healthy.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Ontario, CA, United States
- Founded
- 2020
- Employees
- 14
- Website
- dosedaily.co/
- Ownership
- Privately Held (backing)
Dose doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dose shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dose in its N-PORT filings yet. We sweep new filings monthly.